StockTipsArenaBeta

BUY Alivus Life Sciences Limited — ICICI Securities

BUYAlivus Life Sciences Limited
Alivus Life Sciences share price target & all analyst calls

byICICI SecuritiesHorizon: NA (inferred 1 year)2 Nov 2026via Institutional / Brokerage Research

Entry₹1,447.6Inferred
Target₹1,730
Total upside +19.51%
Stop lossNot given
CMP₹1,480.61d ago
Active+2.28%+16.84%upside left 12 mo left
Follow ICICI Securities for new calls(64% target hit, 1085 closed calls)Get alertsWatch ALIVUS for new buy/sell callsGet alertsSee 541 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Nov, 5:23 pm IST
8 supporting0 opposing
Supports the BUY call (8)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·6 Nov · yesterday

Alivus Life Sciences reported strong Q2FY27 results with 16% YoY revenue growth to Rs 6,820 million and a record EBITDA margin of 41.8%. PAT grew 51.3% YoY to Rs 1,968 million.

BSE · Company Update·29 Oct · 1w ago

(opens in new tab)

Alivus Life Sciences reported a net profit of 1,967.45 million for the quarter ended September 30, 2026, compared to 1,300.26 million in the same quarter of the previous year.

BSE · Board Meeting·29 Oct · 1w ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Alivus Life Sciences

All analyst calls on Alivus Life Sciences

More from ICICI Securities

Every call and its outcome